Manufacturing of Next-Generation Cellular Immunotherapies using a Novel Induced Pluripotent Stem Cell Platform

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. We are pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC platform to derive cell therapy product candidates that can be delivered off-the-shelf for the treatment of a large number of patients. Our novel manufacturing platform and its application to the production of candidate clinical cell therapy products will be presented. Specific challenges in the scale-up and commercialization of off-the-shelf cell therapies will be discussed. Our programs reflect our dedication and commitment to pioneering ground-breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited. Development and application of innovative manufacturing technologies and processes will be pivotal in scaling-up and bringing our novel products to all patients in need.